C.F.R. homeSearch C.F.R.
C.F.R.Title 21Chapter I—Food and Drug Administration, Department of Health and Human ServicesSubchapter D—Drugs for Human UsePart 316—Orphan DrugsSubpart D—Orphan-drug Exclusive Approval

21 C.F.R. § 316.31 (2026)

Scope of orphan-drug exclusive approval

Edition and currency
eCFR text as of Sept. 29, 2026. The text is the edition Syfert holds; for a past event, check the version in force on that date.
Other sources
CURRENTeCFR text as of Sept. 29, 2026 ACTIVE · 4 IN 5Y cited 2014–2026 8citing cases
At a glance

Courts have cited this section in 8 opinions since 2014, 4 of them in the last five years.

(a) FDA may approve a sponsor's marketing application for a designated orphan drug for use in the rare disease or condition for which the drug was designated, or for select indication(s) or use(s) within the rare disease or condition for which the drug was designated. Unless FDA previously approved the same drug for the same use or indication, FDA will not approve another sponsor's marketing application for the same drug for the same use or indication before the expiration of 7 years from the date of such approval as stated in the approval letter from FDA, except that such a marketing application can be approved sooner if, and at such time as, any of the following occurs:

(1) Withdrawal of exclusive approval or revocation of orphan-drug designation by FDA under any provision of this part; or

(2) Withdrawal for any reason of the marketing application for the drug in question; or

(3) Consent by the holder of exclusive approval to permit another marketing application to gain approval; or

(4) Failure of the holder of exclusive approval to assure a sufficient quantity of the drug under section 527 of the act and § 316.36.

(b) Orphan-drug exclusive approval protects only the approved indication or use of a designated drug. If such approval is limited to only particular indication(s) or uses(s) within the rare disease or condition for which the drug was designated, FDA may later approve the drug for additional indication(s) or uses(s) within the rare disease or condition not protected by the exclusive approval. If the sponsor who obtains approval for these new indication(s) or uses(s) has orphan-drug designation for the drug for the rare disease or condition, FDA will recognize a new orphan-drug exclusive approval for these new (not previously approved) indication(s) or use(s) from the date of approval of the drug for such new indication(s) or use(s).

(c) If a sponsor's marketing application for a drug product is determined not to be approvable because approval is barred under section 527 of the Federal Food, Drug, and Cosmetic Act until the expiration of the period of exclusive marketing of another drug, FDA will so notify the sponsor in writing.

[57 FR 62085, Dec. 29, 1992, as amended at 78 FR 35134, June 12, 2013]
The 8 cases that cite 21 C.F.R. § 316.31 most heavily, weighted by court and treatment. RelevanceNewestTreatment
1
GREENEagle Pharm., Inc. v. Alex Azar, II, 952 F.3d 323 (D.C. Cir. 2020).
cites § 316.31 1×cited by 34 cases
Where it cites § 316.31
“The FDA has interpreted “such drug” to mean “same drug,” 21 C.F.R. § 316.31 (a), and has determined that a drug is the “same” as a previously approved drug if it shares the same “active moiety”—the same active ingredient—and “is intended for the same use,” 21 C.”
The case’s holding
The agency cannot impose additional requirements beyond statutory criteria for granting marketing exclusivity to a drug designated and approved under the Orphan Drug Act.
Later courts cite it for
“the text leaves no room for the fda to place additional requirements on a drug that has been designated and approved before granting its manufacturer the right to exclusivity.” · 2 citing courts
2
GREENBraeburn Inc. v. U.S. Food & Drug Admin., 389 F. Supp. 3d 1 (D.C. Cir. 2019).
cites § 316.31 1×cited by 6 cases
Where it cites § 316.31
“21 C.F.R. § 316.31 (a). "Same drug," is defined to exclude any subsequent drug "shown to be clinically superior to the first drug.”
3
cites § 316.31 1×cited by 11 cases
Summary
No passage or summary on file for this case yet.
4
GREENJazz Pharm., Inc. v. Robert F. Kennedy Jr., 141 F.4th 254 (D.C. Cir. 2025).
cites § 316.31 2×cited by 1 case
Where it cites § 316.31
“” See 21 C.F.R. § 316.31 (a); Orphan Drug Regulations, 57 Fed.”
Later courts cite it for
“the words of a statute must be read in their context and with a view to their place in the overall statutory scheme.” · 2 citing courts
5
NO FLAGJazz Pharm., Inc. v. Becerra, No. 2023-1819 (D.D.C. Oct. 30, 2024).
cites § 316.31 3×cited by 0 cases
Summary
No passage or summary on file for this case yet.
6
NO FLAGNeurelis Inc. v. Califf, No. 2024-1576 (D.D.C. Feb. 14, 2025).
cites § 316.31 2×cited by 0 cases
Where it cites § 316.31
“21 C.F.R. § 316.31 (a) (emphasis added). The FDA determined that Valtoco and Libervant were the “same drug,” insofar as they both rely on the same active moiety, 2 diazepam.”
7
NO FLAGBraeburn Inc. v. United States Food & Drug Admin., No. 2019-0982 (D.D.C. July 22, 2019).
cites § 316.31 1×cited by 0 cases
Where it cites § 316.31
“21 C.F.R. § 316.31 (a). “Same drug,” is defined to exclude any subsequent drug “shown to be clinically superior to the first drug.”
8
NO FLAGUcb, Inc. v. Cipla Ltd., No. 1:21-cv-01229 (D. Del. May 15, 2026).
cites § 316.31 1×cited by 0 casesunknown
Where it cites § 316.31
“The FDA granted Nayzilam orphan drug exclusivity under 21 C.F.R. § 316.31 , which expires on May 17, 2026.”

The flag is Syfertize’s treatment of the citing case itself, not of the statute. “Where it cites” is the passage in the opinion; the holding is a summary of the whole case and may concern another point. Annotations are extracted automatically from the opinions in the Syfert caselaw corpus.

Citing cases by year
201420202026

One bar per year. Tallest: 2 cases in 2019. 2026 is a partial year. These are opinions in the Syfert collection, which holds more of some courts’ recent opinions than their older ones, so a rise can reflect what the collection holds and not more litigation.

By court
D.D.C.4D.C. Cir.3D. Del.1
By subsection

Courts have not cited this section by subsection, so its cases are not split up here. The Leading cases tab lists the cases that cite it most heavily.

Enactment and amendments

Syfert holds no separate history line for this section. Where this code prints a source or history note, it appears with the text, usually at the end.

Versions

Edition shown: eCFR text as of Sept. 29, 2026. Syfert holds no earlier or later version of this section.

C.F.R. Home  |  Search C.F.R.  |  Search cases for this section  |  syfert.com